Preclinical News and Research

RSS

OICR makes equity investments in three promising Ontario technologies

Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.

26 Apr 2010

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Pevion Biotech, the Swiss vaccine company, today announced that it has successfully completed the preclinical safety and efficacy studies of its RSV vaccine candidate PEV4. The vaccine candidate is a modern subunit vaccine candidate against respiratory syncytial virus (RSV), which is based on a recombinant RSV-F protein formulated with Pevion Biotech's proprietary and market-validated virosome technology platform.

26 Apr 2010

Symphogen's Sympress II technology demonstrates cost-effective single batch production of rpAb

Symphogen A/S today announced the publication of data in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al. [epub ahead of print] demonstrating the ability of its Sympress II technology to enable cost-effective production of recombinant polyclonal antibodies (rpAb) and antibody mixtures with batch-to-batch consistency that the Company believes could supply drug product for large indications such as cancer and infectious disease.

26 Apr 2010

Mirina closes Versant led Series A-1 financing

Mirina Corporation, a privately held biotechnology company focused on the generation of novel microRNA (miRNA) therapeutics with improved properties, announced today that it has closed a Series A-1 financing. The round was led by new investor Versant Ventures. Previous investors Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital also participated in the round. In conjunction with this financing, Brian Atwood, Managing Director of Versant Ventures, will join the Board of Directors.

26 Apr 2010

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.

26 Apr 2010

Charles River Laboratories International reports 1.4% decline in first-quarter 2010 net sales

Charles River Laboratories International, Inc. today reported its results for the first quarter of 2010. For the quarter, net sales were $297.3 million, a decline of 1.4% from $301.5 million in the first quarter of 2009. The decrease was net of a foreign currency translation benefit of 3.4%. Higher sales for the Research Models and Services (RMS) segment were offset by lower sales for the Preclinical Services (PCS) segment.

26 Apr 2010

RXi Pharmaceuticals to present data on rxRNA therapeutic platform development at upcoming conferences

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development of RXi's next generation rxRNA™ therapeutic platform as well as specific preclinical data generated with this platform.

24 Apr 2010

Johns Hopkins scientist receives AACR Award for Outstanding Achievement in Cancer Research

Joshua T. Mendell, M.D., Ph.D., an associate professor in the McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine, and a Howard Hughes Medical Institute Early Career Scientist, is the recipient of the 30th annual American Association for Cancer Research Award for Outstanding Achievement in Cancer Research.

24 Apr 2010

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.

23 Apr 2010

GenVec's 2009 revenues down 8%: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

23 Apr 2010

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented a poster at the American Association for Cancer Research's 101st Annual Meeting 2010 that details their novel study of molecules that use a tumor's acidic microenvironment to help them tailor chemotherapeutic agents to kill the tumor.

23 Apr 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron Corporation today announced five presentations by Geron scientists and collaborators on the company's telomerase inhibitor, imetelstat sodium, including the drug's activity against cancer stem cells, at the 101st American Association for Cancer Research annual meeting held in Washington D.C.

23 Apr 2010

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.

23 Apr 2010

IAVI, Lentigen to design preventive AIDS vaccine

The International AIDS Vaccine Initiative and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement.

23 Apr 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

23 Apr 2010

CRT teams up with The University of Auckland to discover novel treatments for cancer

Cancer Research Technology - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

MicroStockProfit.com announces investment report featuring Cell Therapeutics

MicroStockProfit.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

22 Apr 2010

Preclinical News and Research

OICR makes equity investments in three promising Ontario technologies

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Symphogen's Sympress II technology demonstrates cost-effective single batch production of rpAb

Mirina closes Versant led Series A-1 financing

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International reports 1.4% decline in first-quarter 2010 net sales

RXi Pharmaceuticals to present data on rxRNA therapeutic platform development at upcoming conferences

Johns Hopkins scientist receives AACR Award for Outstanding Achievement in Cancer Research

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

GenVec's 2009 revenues down 8%: MicroStockProfit.com

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

IAVI, Lentigen to design preventive AIDS vaccine

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

CRT teams up with The University of Auckland to discover novel treatments for cancer

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

MicroStockProfit.com announces investment report featuring Cell Therapeutics

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News